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Abstract
Introduction
In order to estimate the value of interventions in multiple sclerosis (MS) - where
lifetime costs and outcomes cannot be observed – outcome data have to be
combined with costs. This requires that cost data be regularly updated.
Objectives and Methods
This study is part of a cross-sectional retrospective study in 16 countries collecting
data on resource consumption and work capacity, health related quality of life
(HRQoL) and prevalent symptoms for patients with MS. Descriptive analyses are
presented by level of disability, from the societal perspective, in EUR (2015).
Results
A total of 779 patients (mean age 57 years) participated; 72% were below
retirement age and of these, 36% were employed. Employment was related to
disease severity, and MS affected productivity at work for 84% of patients. Overall,
96% and 72% of patients experienced fatigue and cognition as a problem. Mean
utility and annual costs were 0.735 and 11,400GBP at EDSS 0-3, 0.534 and
22,700GBP at EDSS 4-6.5, and 0.135 and 36,500GBP at EDSS 7-9. The mean
cost of a relapse was estimated at 790GBP.
Conclusion
This study illustrates the burden of MS on UK patients and provides current data
on MS that are important for development of health policies.
Wordcount 200
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Introduction
The UK has been a leading force behind the integration of economic studies into
decision making in health care. The academic interest in cost of illness studies,
outcome measurement and cost-effectiveness analysis dates back more than half
a century and a large number of studies have been published. However, the formal
integration into policy and decision-making only happened in 1999 with the
creation of the National Institute for Health and Care Excellence (NICE). Since
then, although its decisions are only applicable to England and Wales, NICE has
been a leader in the development of methodology, and its decisions are observed
with interest across Europe.
A considerable number of cost of illness studies have been performed in multiple
sclerosis (MS) prior to 1999, and new studies were performed around the timing of
introductions of new disease modifying treatments (DMTs).1-5
The availability of disease modifying treatments (DMTs) has led to changes in
patient management and a focus on earlier and better diagnosis and adjustments
in the diagnostic criteria themselves. One of the consequences in this regard is that
the recorded prevalence of the disease is quite different from that estimated two or
three decades ago,6 leading to an increase in prevalence to 203/100,000
population in 2014.7 With diagnosis already possible after a clinically isolated
event,8 one must also expect a different distribution of the type of MS and the
severity of the disease than 10 years ago: a larger proportion of patients with
relapsing remitting disease, and thus of patients in the early stages of the disease
and with less disability (a low score on the Expanded Disability Status Scale,
EDSS).
It is therefore important to update the information on the burden of MS, and the
study presented here is part of a European-wide effort in 16 countries, endorsed by
the European Platform of MS Societies (EMSP) and carried out with the support of
national MS societies.9 It uses a similar methodology as the last European survey
in 2005.10
Materials and Methods
The detailed methodology for the European survey is published separately.11 We
therefore only provide a short summary of the general methods, and issues
specific to the UK.
Data
The study aimed to estimate the costs of all health care and other resource
utilisation related to MS: hospitalisation, rehabilitation, consultations, diagnostic
procedures and tests, medication, community care, family support and production
losses (sick leave, early retirement, invalidity). In addition, information on major
Burden of illness in MS - UK
symptoms such as fatigue and cognition health related quality of life (HRQoL) as
well as self-assessed disability using descriptions based on the Expanded
Disability Status Scale (EDSS) was collected.
Data were collected with a standard questionnaire, at a single point in time, for a
retrospective period of time. The latter was varied depending on the question in
order to minimize recall bias: 1 month for use of drugs, community services and
family help; 3 months for hospitalisation, consultations, tests, sick leave and
relapses; 12 months for major investments. Resource utilisation is reported for
these time periods, while cost calculations are annualized.
Disease information such as the type of MS, disability (EDSS), HRQoL, utility (EQ-
5D12), symptoms (fatigue, cognition) and the effect of MS on work related to the
current day or week.
The handling of missing data for the cost calculation is explained in more details in
the paper describing the study methods.11 For resource use, we present actual
answers without any imputation for missing answers. Also, no imputations were
made for missing information on disease status, symptoms and HRQoL.
Costs
Costs were calculated from the societal perspective, including all costs regardless
of who ultimately is responsible for them. Patient co-payments and patients’ out-of-
pocket expenses were thus included. The cost of a relapse was calculated as the
difference in quarterly costs between patients with or without a relapse and an
EDSS score <6.5; patients who were unsure were excluded from the estimation.
Invalidity, early retirement and DMT costs are not considered in this calculation, as
they are unlikely to be affected within 3 months. In addition, investments in the UK
were essentially for modifications to the house or the car, which again are unlikely
to be affected directly by a relapse.
Unit costs for the individual resources were taken from public sources and are
described in the paper on the study methods.11 Results are reported in GBP
(2015).
Patients
The objective was to include a sample where all levels of disease severity (defined
by EDSS) were represented in sufficient numbers to permit analysis, rather than a
prevalence sample. This highlights how costs and HRQoL change as the disease
progresses and provides the necessary data for cost-effectiveness analysis of
treatments that are expected to change the course of the disease. Mean results
may thus not be representative and should neither be extrapolated directly to
national costs nor be compared directly to the results in earlier studies. We
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therefore report results by disease severity groups only (mild MS EDSS 0-3,
moderate MS EDSS 4-6.5, severe MS EDSS 7-9).
In anonymous surveys, participation will depend heavily on the methods used for
the survey: collecting data in MS centres tends to overestimate the number of
patients with early but severe disease and on treatment with disease modifying
treatments (DMTs); collecting data from members in patient organisations may
lead to the opposite. Internet surveys may bias towards patients with better
education, while postal surveys may include older patients.
The UK participants were contacted by the UK MS society and the vast majority
answered the questionnaire on-line. The data were collected during the third
quarter of 2015. The UK MS Society invited 5,928 individuals by e-mail, but despite
two reminders the response rate reached only 13%.
Results
A total of 779 evaluable responses were received (96% on-line). Patients from all
regions were well represented, with participation in Northern Ireland, Scotland and
Wales proportional to the population. In England, participation from the South East,
South West and London exceeded 40%, and was thus considerably higher than
expected according to population density.13
Table 1 provides details on demographics, employment and disease.
Demographics and employment
The age of respondents in the UK ranged from 26 to 89 years (mean 56.7, median
57, SD 10.8). This makes the UK sample the oldest in our study series with a clear
effect on the results - more patients with severe disease, lower DMT usage, fewer
patients of working age and actually working. These differences make comparisons
of mean costs in the sample with those from other countries in this study neither
meaningful nor informative.
Women represented 70% of the sample; 80% of the sample lived with their family
and eight patients were in a nursing home at the time of the survey. Education
levels in our sample appeared to be high: 10% of patients had basic education,
52% had a secondary or a professional degree, and 38% a university degree. This
compares to 36%, 37% and 27% in the general population in England and Wales
in 2011,14 and would indicate a sample with high education, as would be expected
on an internet survey.
Despite the high mean age, a majority of patients in the sample were below
average effective retirement age (63 years for women, 64 years for men15)
numbering 563 patients (72%). Of these, 200 patients (36%) were employed or
self-employed. Fourteen patients above retirement age also worked, bringing this
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group to 214 patients (or 28% of the full sample), with a mean age of 50.8 years.
The employment rate compares to an activity rate of 74.4% in the general
population aged 16-64.16 The majority of patients worked part time (92%), and of
these, 82% did so because of MS. In the general population, 27% of people work
part-time and of these, 3% indicated that it was due to illness or disability,14
illustrating again how much MS affects patients’ activities. Average working hours
in the sample were 39 hours for full-time workers, 21.4 hours for part time
employees. Sick leave during the past 3 months was reported by 22% of patients,
with a mean duration of 9.2 days. This appears to be mostly due to relapses that
were reported by 18% of patients.
Overall, employment decreased rapidly with increasing disease severity, as shown
in Figure 1. The reasons for the difference found between patients at EDSS 2-3
and EDSS 4-5 might partly be due to the skewed disease severity distribution in
this sample. The number of patients with an EDSS of 0-3 was small, with however
a relatively high age (52 years) and a long mean disease duration (14-18 years)
that may explain their leaving the work force for reasons other than a physical
handicap (fatigue, cognition). Of non-employed patients, 57% indicated MS as the
reason.
Most employed patients felt that MS affected their productivity at work (84%) and
only 8% indicated that they had no problems, while 8% had not answered the
question. The severity of the effect covered the entire VAS range from 0 to 10, with
a mean of 4.0 (SD 2.7) (Figure 2). Fatigue was considered the most bothersome
symptom (73%), followed by difficulties thinking (43%), mobility (40%), pain (31%)
and low mood (21%).
Disease information
Disease information is summarized in Table 1. The mean EDSS in the sample was
5.5 (SD 2.2), with 64% of patients at EDSS 6 or higher. This makes it the most
severe sample in the European study. However, the number of patients at all levels
of EDSS was sufficient to yield a stable analysis, with the exception of EDSS 9 (10
patients). The mild group represented 18% of the sample, the moderate group 51%
and the severe group 31%.
The proportion of patients with relapsing-remitting disease (RRMS) was 37%, with
secondary progressive disease (SPMS) 38% and with primary progressive (PPMS)
24% (14 missing). Thus, while one would expect a high proportion with SPMS
considering the high EDSS, the proportion stating PPMS is considerably higher
than normal prevalence.6 This suggests, as we found in previous studies, that
patients might be uncertain in their answers regarding the type of disease. We
therefore did not include disease type in our analyses and focused instead on
EDSS levels. DMTs were used by 28% of the sample, with usage declining with
higher EDSS levels, as expected (Table 1). Amongst users, 13% were on their first
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DMT treatment, likely again an expression of the high age and severe disease in
this sample; first-generation DMTs were used by 58% of users (Table 2).
Relapses in the preceding 3 months were reported by 141 patients (18%) of which
half occurred in the past month (Table 1). However, 176 patients (23%) were
unsure whether they had a relapse or not, and we assumed that the answer was
no. Thus the mean relapse rate over a 3 month period was estimated at 0.3 (SD
0.7). Corticosteroids were used by 25 patients (18%) with relapses.
Symptoms and HRQoL
Fatigue and cognitive difficulties were an issue for a majority of patients, and both
were related to disease severity (Figure 2). Fatigue was present in 96% of patients.
The mean VAS score was 5.9 (SD 2.5) for the sample and 4.4 for patients with
mild disease and 6.2 for patients in the moderate and severe groups. Cognitive
difficulties were recognized by 72% of patients. The mean VAS score in this group
was 4.8 (SD 2.0) overall, 4.4 in the mild, 4.8 in the moderate and 5.0 in the severe
group. For the full study sample (assigning 0 to the group with no problems) the
mean score was 3.5 (SD 2.9) and 2.8, 3.6 and 3.7 in the three groups,
respectively.
The detailed answers to the EQ-5D indicated that both the severity and the
domains affected changed with disease severity.17 Self-care was unaffected in
patients with mild disease, but declined rapidly with advancing disease. Anxiety
was present in around half of the patients at all levels. For the other three domains,
around half of the sample indicated problems already in early disease, with a rapid
decline at higher EDSS levels (Figure 3).
Utility
Utility declined with increasing disability (EDSS) (Figure 4). Mean utility in the
sample was 0.469 (SD 0.3), the lowest in this European study and explained
mostly by the high EDSS.
Resource utilisation
During the preceding three months, 28 patients (4%) were admitted as inpatients,
most often in a general ward (25 patients), on average 2.3 (SD 1.6) times and for a
mean of 6.5 (SD 6.6) days. Fifty-five patients (7%) had day admissions, on
average 2.5 (SD 1.9) times. Inpatient or day admissions to rehabilitation centres
occurred for 17 patients (2%).
Two thirds of patients (524, 67%) had a consultation during the past three months,
most often with a general practitioner (262, 34%), an MS nurse (209, 27%) or a
neurologist (195, 25%). Investigations and tests were needed by 120 patients
(15%) and medications for MS and MS related symptoms were used by 73% of
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patients during the past month. Drugs other than DMTs and corticosteroids were
used by 284 patients (37%), predominantly treatments for walking, spasticity and
pain (199 patients, 26%), for incontinence (126 patients, 16%) and for depression
(109 patients, 14%). Non-prescription drugs were purchased by 420 (54%) patients
(Table 3).
Investments in equipment and devices to aid patients’ mobility were made during
the past 12 months for or by 380 patients (49%), most often for walking aids, wheel
chairs and modifications to the car or the house.
Community and social services were used by 22% of patients, most frequently
home help and transportation. Help from family was used by 69% of patients, on
average 19.3 days per month and 4.9 hours per day. Both community services and
informal care were related to disease severity (Figure 5).
Costs
Total mean annual costs per patient for patients with mild, moderate and severe
disease and by EDSS score are presented in Figure 6 and Table 4.
The average cost of a relapse for patients with an EDSS up to 6 was estimated at
792GBP. All types of costs, but particularly informal care, increased for patients
with relapses (Figure 7).
Discussion
This study provides an update to current understanding of the burden of MS on
patients, the healthcare system, and society in general, based on a cross-sectional
survey conducted in 2015.
The resource utilisation patterns reported here reflect the clinical needs and
disease experience of patients in the UK. As was observed in previous studies of
this type, we report relatively high levels of utilisation of MS nursing services and
reliance on over the counter medication and informal care among study
respondents. DMT use is lowest amongst the countries participating in this study,
but is partly explained by the underrepresentation of people with RRMS and a
short disease duration. These findings should be evaluated with reference to local
clinical guidelines, such as those published by the ABN in 2015,18 or by
benchmarking versus the findings from other countries in this research programme.
It is also important to note that, in addition to clinical needs, these patterns reflect
the structure of healthcare provision and delivery of various services through the
UK NHS. That is, patients utilise the particular set of services and treatments that
are commissioned by the NHS, which is not necessarily the same as that provided
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to equivalent patients in other countries. Similarly, cultural norms also impact on
how often a person will seek to visit their GP, and their willingness to present with
symptoms of early disease prior to a confirmed diagnosis. Thus, comparisons of
these findings with those from other countries should be interpreted with caution.
It is nevertheless possible to comment on some notable aspects of the data
presented here. This is a relatively old sample of MS patients, and the distribution
of EDSS scores does not represent current prevalence. Patients with severe
disease and long disease duration are overrepresented and thus introduce a bias
in the mean analysis for the total sample. We partly overcome this bias by
presenting all results by disease severity rather than for the sample, but
acknowledge that the survey underrepresents people with shorter disease
duration, of whom there will be many with relapsing remitting MS and mild
disability.
The mean time to diagnosis in this UK sample was 8 years. This is likely a
reflection of the high age of the sample where patients received their diagnosis
some 15 years ago, at which time diagnostic criteria were used that did not allow
as early a diagnosis as is nowadays possible, and when a “wait-and-see” approach
to clinical care of patients with MS was more likely. More recent and emerging
evidence suggests longer term benefits of disease modifying treatments,19
potentially more so with early treatment.20 Although disease modifying treatments
are a major cost item in mild MS, the observation of the large increase in costs,
alongside the severe drop in utility in patients with severe disease as demonstrated
in this work, suggests the potential for such treatments to ultimately result in fewer
costs and better health outcomes for the NHS.
In addition to characterising various aspects of the burden of MS on patients, and
capturing patterns of resource utilisation that could inform future policy
recommendations, this work can provide valuable inputs into cost-effectiveness
analyses for appraisals by NICE and similar bodies. The data generated by this
study provides a comprehensive and contemporary source to describe the HRQoL
and resource utilisation patterns of patients in the UK with MS. The level of detail in
which the cost items are captured and described is a strength of this study; the
methodology underlying the calculations is clearly laid out. The cross-sectional
approach to data collection is mandated by the fact that the disease process of MS
and related resource consumption cannot be observed over its entire duration, and
covering the entire disease spectrum is key. This is seldom, if ever, possible even
in randomized controlled trials. Also, the extent to which pivotal studies capture
healthcare resource utilisation is patchy; furthermore, RCT populations may not
reflect the true complexity of real world patients with MS, in terms of their clinical
profiles or their experience of the health and social care system outside the context
of a clinical study.
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The UK has seen a number of cost of illness assessment studies in MS, and a
number of data sets have been used in NICE appraisals. However, the most recent
of these studies suffers from a much smaller data set,5 while the larger research
efforts were conducted in 2005 against the background of a different NHS.4, 21, 22
Simply inflating the values extracted from that earlier study to suit today’s needs is
no longer satisfactory and this update is timely.
In summary, these data provide the latest and most comprehensive source of
information on the burden of MS among UK patients. The data provided can help
direct future design of healthcare provision and policy changes, but decision
makers should interpret the findings carefully and be aware of the limitations of this
approach. Moreover, a range of factors make inter-country comparisons of data
from this research initiative difficult. In particular, the patient group represented is
the oldest of all included countries, suggesting that younger patients with mild MS
and short disease duration are underrepresented in this survey.
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Table 1 – Sample demographics
Sample Mild MS
EDSS 0-3
Moderate MS
EDSS 4-6.5
Severe MS
EDSS 7-9
Missing
EDSS
N
779 144
(18.5%)
394
(50.6%)
240
(30.8%)
1
Proportion women
70.1% - - -
Proportion living alone
18.6% 29 (20.1) 85 (21.6) 31 (12.9)
Mean age (SD)
56.7 (10.8) 52 (10.9) 56 (10.5) 61 (9.6)
Education
- Primary school
9.6% - - -
- High school degree
27.0% - - -
- Professional diploma
24.8% - - -
- University education
38.4% - - -
Employment
- Patients of working age 563 (72.3%1) 125 (86.8%) 300 (76.1%) 137 (57.1%) 1
- Total currently employed or self-employed 214 (27.5%1) 84 (58.3%) 112 (28.4%) 17 (7.1%) 1
- Working age, employed or self-employed
200 (35.5%2) 78 (62.4%) 107 (35.7%) 14 (10.2%) 1
- Working full time
17 (7.9%3) 9 (10.7%) 6 (5.4%) 1 (5.9%) 1
- On long-term leave (>3<12 months)
10 (4.7%3) - - -
- Sick leave (past 3 months) 47 (22.0%3) - - -
- Not working due to MS
311 (55.2%2) - - -
- Invalidity pension 109 (19.4%2) 4 (3.2%) 69 (23.0%) 36 (26.3%)
- Early retired 155 (27.5%2) 18 (14.4%) 77 (25.7%) 60 (43.8%)
Disease information
- Mean age at diagnosis (SD) 40.17 (10.88) 38 (10.1) 40 (10.8) 42 (11.3)
- Mean age at first symptoms (SD) 32.23 (11.16) 32 (10.6) 32 (10.9) 33 (12.0)
- Mean EDSS (SD) 5.5 (2.2) 1.6 (1.0) 5.7 (0.8) 7.5 (0.6)
- Proportion with RRMS
286 (36.7%) - - -
- Proportion with relapses
141 (18.1%) 30 (20.8) 75 (19.0) 35 (14.6) 1
- Proportion using DMTs
218 (28.0%) 46.5% 32.0% 10.4%
SD=Standard deviation, EDSS=Expanded disability status scale
1of total sample (n=779); 2of patients of working age (N=563); 3of patients working (N=214); 4Missing (N=1)
Table 2 - Type of DMTs used (N=2181)
First-generation treatments % of total users Second generation treatments % of total users
interferon-beta 1b (Betaferon®/Extavia®) 3.7% natalizumab (Tysabri®) 15.6%
interferon-beta 1a (Avonex®) 10.6% fingolimod (Gylenia®) 11.5%
interferon-beta 1a (Rebif®) 18.3% teriflunomide (Aubagio®) 1.8%
glatiramer acetate (Copaxone®) 22.5% dimethyl fumarate (Tecfidera®) 14.7%
peginterferon-beta 1a (Plegridy®) 0.9%
mitoxantron (Novantrone®) 1.4%
azathioprine (Imurel®) 0.5%
DMT=Disease modifying treatment
1 Missing information on DMT for 3 patients
Table 3 – Resource utilisation, health care and community services
Users
% of
sample
Mean
number of
times (SD)
Mean
number of
days(SD)
Hospitalisation (3 months)
Inpatient admission 28 3.6%
- neurology ward 8 1.0% 2.25 (1.58) 6.5 (6.6)
- other wards 25 3.2% 2.28 (1.90) 4.5 (6.1)
Day admission 55 7.1%
- neurology ward 33 4.2% - 2.3 (1.9)
- other wards 33 4.2% - 2.2 (2.0)
Rehabilitation centre 17 2.2%
- inpatient admission 7 0.9% - 4.0 (7.8)
- day admission 15 1.9% 4.3 (3.6)
Nursing home 17 2.2% 26.9 (31.9)
Consultations (3 months)
Any type of consultation 524 67.3%
Neurologist 195 25.0% 1.4 (1.2) -
Internist 3 0.4% 1.0 (0.0) -
Urologist 65 8.3% 1.6 (0.8) -
Ophthalmologist 26 3.3% 1.5 (0.8) -
Psychiatrist 11 1.4% 2.5 (2.2) -
General practitioner 262 33.6% 2.3 (2.2) -
MS nurse 209 26.8% 2.0 (4.6) -
Continence advisor 68 8.7% 2.1 (1.8) -
Physical therapist 150 19.3% 5.2 (5.0) -
Occupational therapist 47 6.0% 2.5 (1.6) -
Speech therapist 10 1.3% 1.9 (1.6) -
Acupuncturist 15 1.9% 4.9 (3.6) -
Chiropractor 13 1.7% 3.8 (3.1) -
Counsellor 24 3.1% 4.0 (2.7) -
Homeopath 10 1.3% 2.4 (1.3) -
Massage therapist 53 6.8% 5.9 (9.1) -
Telephone consultation MS nurse 141 18.1% 2.1 (2.6) -
Telephone consultation neurologist 11 1.4% 1.5 (0.8) -
Tests (3 months)
Any kind of test 120 15.4%
MRI (brain) 40 5.1% - -
MRI (spine) 25 3.2% - -
Ultrasound 21 2.7% - -
Blood tests 82 10.5% -
Medication (1 month)
Any kind of medication 572 73.4% - -
DMTs 218 28.0% - -
Corticosteroids 25 3.2% - -
Symptomatic prescription drugs 284 36.5%
- Walking, spasticity, pain treatment 199 25.5% - -
- Urological treatments 126 16.2% - -
- Fatigue treatments 35 4.5% - -
- Depression treatments 109 14.0% - -
OTC drugs 420 53.9% - -
Equipments, aids, modifications
(12 months)
Any type 380 48.8%
Lifts, elevators, ramps, rails 120 15.4% -
Walking aids 171 22.0% -
Wheelchair use (manual, electric) 181 23.2% -
House and car modifications 202 25.9% -
Community services (1 month)
Any kind of service 168 21.6%
Home help (days) 106 13.6% - 16.92 (11.7)
Transportation (trips) 74 9.5% - 8.74 (9.0)
SD=Standard deviation; MRI=Magnetic resonance imaging; DMT=Disease modifying treatment;
OTC=Over the counter drug
Table 4 – Total mean annual cost per patient by disease severity (mild, moderate, severe), N=779 (GBP 2015)
Mild Moderate Severe
EDSS 0-3 EDSS 4-6.5 EDSS 7-9
mean (SD), GBP mean (SD), GBP mean (SD), GBP
Total costs 11,400 (14,900) 22,700 (20,000) 36,500 (26,200)
Health care 5,903 (8,599) 5,511 (7,547) 5,039 (9,941)
Inpatient care 421 (4,673) 195 (1,384) 1,830 (8,644)
Day admission 321 (2,021) 399 (1,967) 311 (1,266)
Consultations 705 (1,504) 1,188 (1,770) 1,322 (1,996)
Tests 77 (259) 81 (276) 80 (295)
Medication 172 (383) 250 (597) 337 (890)
DMTS 4,206 (5,292) 3,397 (5,618) 1,160 (3,585)
Services and informal
care cost 1,050 (4,601) 6,924 (10,132) 19,624 (19,257)
Community services 100 (525) 865 (3,837) 5,786 (13,477)
Investments 366 (4,167) 1,618 (5,785) 2,500 (6,144)
Informal care 585 (1,719) 4,441 (6,507) 11,337 (10,469)
Total medical and non-
medical direct cost 6,953 (10,715) 12,435 (13,531) 24,662 (21,895)
Short term absence 191 (1,117) 118 (834) 0 (0)
Long term absence,
invalidity, early retirement 4,289 (10,009) 10,166 (12,937) 11,875 (13,831)
Total production losses 4,480 (9,989) 10,284 (12,871) 11,875 (13,831)
GBP=British Pound; EDSS=Expanded Disability Status Scale; SD=Standard deviation; DMT=Disease modifying treatment
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Figure legends UK
Figure 1 – Proportion of patients below retirement aged employed or self-
employed. 563 patients (72%) were below retirement age and of these, 36%
were employed or self-employed.
Figure 2 – Mean score on the visual analogue scales (0=no problem;
10=severe problems) for fatigue, cognitive difficulties and impact of MS at
work (only for patients working). Patients with missing EDSS (1) or missing
answers are excluded.
Figure 3 – Proportions of patients at different levels of disease severity
experiencing difficulties in the five domains of the EQ-5D. Difficulties are
increasing with increasing disease severity, with the exception of
anxiety/depression that appears similar at all stages of the disease.
Figure 4 – Utility by EDSS level using the EQ-5D. Utility is calculated by
relating the scores (1=no problem; 2=some problems; 3=severe problems) of
the five domains to a health state valuation system established with the
general population using decision analytic methods.15 Values decrease from
levels comparable to the population to negative values in severe disease.
Figure 5 – Intensity of use of informal care (number of days and hours per day
during the past month). 69% of the sample use help from the family, but use is
clearly concentrated in the severe group: 26% of patients in the mild, 74% in
the moderate and 86% in the severe group are relying on family support.
Figure 6 – Mean total annual costs per patient by level of EDSS. Total costs
increase with disease severity, but the type of resources change. Overall,
health care costs dominate in mild disease; production losses, informal care,
investments and community services dominate in more severe disease.
However, due to the underrepresentation of younger patients with a short
disease duration, production losses are already high at low EDSS levels,
while the cost of DMTs is lower than expected.
Figure 7 – Mean 3-month cost of a relapse, estimated as the difference of
costs of patients below EDSS 6.5 with and without a relapse (N=83 and
N=367, respectively). Patients who were unsure (N=176, 23%) were excluded
from the estimation. Invalidity, early retirement and DMT costs are not
considered in this calculation, as they are unlikely to be affected within 3
months. In addition, we excluded investment costs as they related for their
vast majority to transformations of the car or house unlikely to be affected by
a relapse. The cost of a relapse is thus estimated at 792GBP. The use of all
types of resources increases during a relapse, with the biggest increase seen
for inpatient care (22%) and informal care (24%).
Burden of illness in MS, 2015 – United Kingdom
Figure 1 – Employment by disease severity.
EDSS=Expanded Disability Status Scale
0%10%
20%30%
40%50%
60%70%
80%90%
100%
0 1 2 3 4 5 6 6.5 7 8 9
Propor
tionof
patient
sofwo
rkinga
geemp
loyed
EDSS
Workforce participation (patients below retirement age)Proportion of sample belowretirement ageProportion below retirement ageemployed/self-employed
Figure 2 – Fatigue, cognitive difficulties, effect of MS on productivity at work.
EDSS=Expanded Disability Status Scale
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Figure 3 – Problems in different domains of HRQoL (EQ-5D), N=772
EDSS=Expanded Disability Status Scale; QoL=Quality of life; EQ-5D=EuroQoL-5 dimensions
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Figure 4 – Utility by EDSS (N=772)
ED-5D=EuroQoL-5 dimensions; EDSS=Expanded Disability Status Scale
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Figure 5 – Use of informal care (days per month and hours per day, per user)
EDSS=Expanded Disability Status Scale
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Figure 6 – Total mean annual cost per patient by disease severity (N=779)
GBP=British Pound; EDSS=Expanded Disability Status Scale
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Figure 7 – Relapse costs (3 months) GBP 2015
GBP=British Pound; EDSS=Expanded Disability Status Scale
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